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Abstract
 
A dysregulated inflammatory response in the central nervous system (CNS) lies at the heart of many neuropatho-
logical conditions such as multiple sclerosis and Alzheimer’s disease. A key component of these inflammatory
conditions is the accumulation of leukocytes in the CNS. The infiltration of leukocytes into the brain is dependent
on the induction of leukocyte adhesion molecules and chemoattractant chemokines. Recent studies have sug-
gested the astrocyte to be a key cell in mediating the inflammatory process in the brain and in expressing adhesion
molecules and chemokines. Here I overview work in my laboratory and others that demonstrates interleukin-1 (IL-
1) to be a key inducer of the expression of these molecules in astrocytes. The temporal expression is sustained in
nature and this is due to prolonged activation of the transcription factor NF
 
κ
 
B. The molecular basis to the sustained
activation of NF
 
κ
 
B is also discussed. The IL-1 signalling pathway thus emerges as a valuable therapeutic target in
the treatment of presently incurable neuropathological conditions.
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Introduction
 
Neurological disorders represent some of the most
debilitating diseases known. Many of these diseases are
underpinned by a dysregulated inflammatory response
in the central nervous system (CNS). Inflammation is
normally a defence system in the body that protects
against invasion by foreign agents and repairs tissue
damage. However, it is imperative that this process is
tightly controlled. The inappropriate or chronic deploy-
ment of the inflammatory system can lead to a loss of
its protective and reparative function and its emergence
as a destructive force in pathogenic processes such as
multiple sclerosis and Alzheimer’s disease. In an effort
to develop urgently needed therapeutic agents for
these currently incurable diseases, it is necessary to
probe the cellular and molecular components of the
inflammatory network that facilitates and drives the
inflammatory process in the brain. This article will
explore the cytokine interleukin-1 (IL-1) as a key player
in neuroinflammation and will especially focus on its
pro-inflammatory effects on astrocytes.
 
Inflammation in the brain
 
Inflammation forms an integral part of the innate
immune system. It is triggered in response to infection,
damage and ischaemia. The cardinal signs of inflamma-
tion are redness, swelling, pain and heat, all of which
result from the vascular response in which vasodilation
and increased vascular permeability allow for the move-
ment of soluble mediators and leukocytes from the
blood vessel lumen to the site of inflammation. The
arrival of leukocytes at the site of infection and/or
damage is followed by their release of degradative
enzymes and reactive oxygen species, ultimately lead-
ing to the destruction of the invading agent and dam-
aged tissue and allowing for tissue repair. However, it is
crucially important that the recruitment of leukocytes
into tissue is strictly regulated because the effector sys-
tems used by these cells in eliminating the foreign body
are also potentially toxic to normal tissue. Thus the
chronic recruitment and retention of leukocytes in tissues
will lead to tissue destruction and disease. This is evident
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in multiple sclerosis, in which pathology is accompanied
by a strong infiltration of the CNS by pro-inflammatory
leukocytes (Traugott et al. 1983; Hafler & Weiner, 1987).
Much effort has been invested to understand the
mechanistic basis to the leukocyte recruitment process.
The pro-inflammatory cytokines, IL-1 and tumour
necrosis factor (TNF), are crucially important in mediat-
ing the infiltration of tissue by leukocytes, via the initial
induction of leukocyte adhesion molecules such as
vascular cell adhesion molecule-1 (VCAM-1), intercellu-
lar cell adhesion molecule-1 (ICAM-1) and E-selectin on
endothelial cells (Bevilacqua, 1993; Ramilo et al. 1990).
IL-1 and TNF are primarily produced by monocytes and
macrophages but can also be generated by a variety of
resident cells in tissues (Rothwell & Luheshi, 2000). The
induction of adhesion molecules by these cytokines
allows for the adhesion of leukocytes to endothelial cells.
The endothelium retracts, allowing for the migration
of the transiently adhered leukocytes into the inflamed
tissue in response to chemoattractant cytokines that
are also induced by IL-1 and TNF. It is clear that the
induction of adhesion molecules and chemokines by these
pro-inflammatory cytokines orchestrates the recruit-
ment process and many studies suggest that such
induction is at the centre of promoting chronic infiltra-
tion of leukocytes in the CNS, leading to neuropatho-
genesis. Thus the brain levels of IL-1 and TNF increase
dramatically in neuropathological states (Hofman et al.
1986; Dinarello, 1991) and increased levels of these
cytokines are associated with breakdown of the blood–
brain barrier and recruitment of neutrophils into the
CNS (Ferrari et al. 2004). Neutralizing antibodies to the
two cytokines reduce the CNS accumulation of leuko-
cytes in neuropathology (Ramilo et al. 1990). Further-
more, the adhesion molecules VCAM-1 and ICAM-1 are
elevated in multiple sclerosis lesions and make a major
contribution to the extravasation of leukocytes across
the blood–brain barrier (Brosnan et al. 1995; Cannella
& Raine, 1995). The importance of adhesion molecules
in neuropathology is clearly evident by a study describ-
ing that an antibody that blocks the interaction of
leukocytes with VCAM-1 also reduces the severity of
experimental multiple sclerosis (Yednock et al. 1992).
 
The astrocyte and its role in leukocyte 
migration into brain
 
Although leukocyte–endothelial interactions are cru-
cial to the leukocyte migration process, various lines of
evidence strongly suggest that the astrocyte is a key cell
type that facilitates leukocyte recruitment to the CNS.
Firstly, the prominent expression of leukocyte adhesion
molecules in astrocytes is restricted to conditions
such as multiple sclerosis (Cannella & Raine, 1995) and
Alzheimer’s disease (McGeer & McGeer, 2003), in which
leukocyte infiltration in the CNS is high. Secondly,
strategies that interfere with the adhesive function of
adhesion molecules inhibit leukocyte–astrocyte inter-
actions (Hery et al. 1995) and reduce the severity of
experimental multiple sclerosis (Yednock et al. 1992).
Thirdly, whereas astrocyte expression of chemokines is
negligible in the normal CNS, a wide variety of chemo-
kines are expressed by astrocytes in a number of CNS
diseases, including multiple sclerosis, Alzheimer’s
disease and Parkinson’s disease (Dong & Benveniste,
2001). Thus the induction of chemokines and adhesion
molecules in astrocytes is likely to make a major contri-
bution to the recruitment and retention of leukocytes
in the CNS, the prologue to neuropathology. I and
others have shown that the pro-inflammatory cytokine
IL-1 is a key stimulus in the induction of adhesion
molecules and chemokines in astrocytes (Moynagh et al.
1994; Shrikant et al. 1994; Rosenman et al. 1995; Bourke
& Moynagh, 1999). Interestingly, my studies have shown
that IL-1 induces sustained expression of the chemoat-
tractant cytokine IL-8 and the adhesion molecules
VCAM-1 and ICAM-1 in astrocytes (Moynagh et al. 1994;
Bourke & Moynagh, 1999). Such sustained expression
may underlie the chronic nature that is typical of the
CNS inflammatory response in the neuropathological
conditions mentioned above. I have thus attempted to
address the molecular basis to the prolonged induc-
tion of these pro-inflammatory proteins in astrocytes.
 
IL-1 causes sustained activation of NF
 
κ
 
B in 
astrocytes
 
The transcription factor NF
 
κ
 
B is a crucial mediator in
the IL-1 signalling pathway and acts as a major driving
force behind the induction of adhesion molecules and
chemokines (Moynagh et al. 1994; Bourke & Moynagh,
1999). The study of the temporal activation of NF
 
κ
 
B by
IL-1 in astrocytes has shed important light on the likely
mechanism dictating prolonged expression of adhe-
sion molecules and chemokines in response to IL-1 in
these cells (Fig. 1).
NF
 
κ
 
B exists in the cytosol of resting cells as a homo-
or heterodimer of proteins of the Rel family of
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transcription factors (Blank et al. 1992; Narayanan
et al. 1993). The transcriptional activity of the Rel pro-
teins is tightly regulated by their association with mem-
bers of the inhibitory molecule family I
 
κ
 
B (Baeuerle &
Baltimore, 1988). The most extensively characterized
isoforms are I
 
κ
 
B-
 
α
 
, I
 
κ
 
B-
 
β
 
 and I
 
κ
 
B-
 
ε
 
 (Thanos & Maniatis,
1995). The I
 
κ
 
B proteins sequester NF
 
κ
 
B in the cytosol by
masking its nuclear localization signal (NLS) and also
prevent NF
 
κ
 
B from binding to DNA by masking its DNA-
binding domain. Exposure of cells to pro-inflammatory
stimuli such as IL-1 causes phosphorylation of I
 
κ
 
B on
two specific N-terminal serines by the I
 
κ
 
B-kinases (IKK),
IKK
 
α
 
 and IKK
 
β
 
, which are activated by a complex signal
transduction pathway (May & Ghosh, 1998). The phos-
phorylation of I
 
κ
 
B proteins represents a signal for ubi-
quitin conjugation, followed by their degradation via
the 26S proteosome (Traenckner et al. 1994, 1995). This
allows for translocation of NF
 
κ
 
B to the nucleus, where
it activates the promoter regions of genes, especially
those encoding pro-inflammatory proteins such as
adhesion molecules and chemokines (Beg et al. 1993;
Henkel et al. 1993).
Following stimulation, the duration of NF
 
κ
 
B activa-
tion may be transient or persistent, depending on the
cellular stimulus and cell type. The temporal profile is
of considerable clinical relevance because sustained
activation of NF
 
κ
 
B has been demonstrated to be asso-
ciated with chronic inflammatory diseases (Bureau et al.
2000). Interestingly, it has recently been shown that
NF
 
κ
 
B activation is sustained in astrocytes in response to
stimulation with IL-1 (Bourke et al. 2000). Again, this is
of clinical relevance because the sustained activation of
NF
 
κ
 
B in brain cells will lead to prolonged induction of
leukocyte adhesion molecules and chemokines (Bourke
& Moynagh, 1999) that will facilitate cerebral recruit-
ment of leukocytes culminating in the generation of
neuropathological states as described above. Thus the
mechanisms controlling the temporal activation of
NF
 
κ
 
B by IL-1 in astrocytes have been probed. The study
shows that the I
 
κ
 
B isoforms (
 
α
 
, 
 
β
 
 and 
 
ε
 
) play key roles
in regulating the longevity of NF
 
κ
 
B activity in astro-
cytes (Bourke et al. 2000). Thus stimulation of these
cells with IL-1 causes rapid but transient degradation
of I
 
κ
 
B-
 
α
 
 and I
 
κ
 
B-
 
ε
 
. However, NF
 
κ
 
B remains active even
after these I
 
κ
 
B isoforms have returned to control levels.
By contrast, the I
 
κ
 
B-
 
β
 
 isoform fails to reappear following
its initial degradation by IL-1, coincident with sustained
activation of NF
 
κ
 
B. In addition, 
 
in vivo
 
 overexpression
of the various I
 
κ
 
B isoforms revealed that I
 
κ
 
B-
 
β
 
 is the
only isoform that has the ability to inhibit IL-1-induced
NF
 
κ
 
B-driven transcription. Hence the activation of
NF
 
κ
 
B by IL-1 in astrocytes is sustained due to the inabil-
ity of the newly synthesized I
 
κ
 
B-
 
α
 
 and I
 
κ
 
B-
 
ε
 
 to inhibit
NF
 
κ
 
B coupled to the prolonged disappearance of I
 
κ
 
B-
 
β
 
in response to IL-1 (Fig. 1). As sustained activation of
NF
 
κ
 
B is likely to lead to a chronic inflammatory state,
the temporal regulation of NF
 
κ
 
B in astrocytes may pro-
vide a means for controlling inappropriate deployment
of the inflammatory response in diseases such as
multiple sclerosis.
Fig. 1 Model for sustained activation of 
NFκB by IL-1 in astrocytes. Engagement 
of the IL-1 receptor (IL-1R) leads to 
activation of IκB-kinases and subsequent 
phosphorylation and degradation of the 
various IκB isoforms. NFκB translocates 
to the nucleus and induces the 
expression of leukocyte adhesion 
molecules, chemokines, IκB-α, IκB-ε but 
not IκB-β. The form of NFκB that is 
susceptible to inhibition by IκB-β thus 
remains bound to DNA for sustained 
periods of time.
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IL-1 as a therapeutic target in 
neurodegeneration
 
It is clear from above that the IL-1 signalling presents
itself as a potential therapeutic target in the treatment
of neurodegenerative disorders. Indeed, studies have
reported that polymorphisms in genes encoding IL-1
are associated with an increased risk of early onset
Alzheimer’s disease (Grimaldi et al. 2000; Nicoll et al.
2000). It is interesting to note that anti-inflammatory
glucocorticoids, which have value in the treatment
of some neuropathological conditions (McGeer et al.
1996), can induce the expression of I
 
κ
 
B proteins and
thus inhibit IL-1 activation of NF
 
κ
 
B (Auphan et al. 1995;
Scheinman et al. 1995). This may at least partly contrib-
ute to the anti-inflammatory effects of steroids in the
CNS. Perhaps more compelling findings in support of
the IL-1 pathway as a valuable target in neuroprotec-
tion come from various 
 
in vivo
 
 studies in which the pro-
tective effects of various agents that specifically inhibit
the IL-1 pathway were assessed in models of cerebral
ischaemia or mechanical injury (Rothwell, 1999; Touzani
et al. 1999). Such agents included the highly specific
and endogenous IL-1 receptor antagonist (IL-1ra), neu-
tralizing IL-1 antibodies and inhibitors of the process-
ing of immature IL-1 into the mature and active IL-1
form. These agents achieved a considerable reduction
in neuronal loss in the various rodent models. Interest-
ingly, IL-1ra, the most specific and effective blocker of
IL-1, improved neurological function after injury and
this was associated with attenuation of neutrophil
invasion (Rothwell, 1999). These studies strongly
suggest that IL-1 plays a key role in promoting neuro-
degeneration, and interventative stratagies that regu-
late IL-1 signalling may emerge to be of great clinical
value.
 
Conclusions
 
The dysregulated inflammatory response lies at the
heart of many neuropathological conditions. Because
cytokines such as IL-1 orchestrate the inflammatory
response it is not surprising that accumulating evidence
is making a compelling case for a key role for IL-1 in
the generation of neurological disorders. A complete
understanding of the molecular mechanisms by which
IL-1 produces its effects in the CNS will aid greatly in
the design of novel therapies for the treatment of cur-
rently incurable inflammatory diseases of the brain.
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